Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis

Journal of Clinical Apheresis

Volumn 16, Issue 2, 2001, Pages 82-87

  Korbling M ^a   Giralt, S ^a   Khouri, I ^a   Mirza, N ^a   Donato, M ^a   Anderlini, P ^a   Fischer, H ^a   Andreeff, M ^a   McMannis, J ^a   Champlin, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Blood stem cell apheresis; CD3 positive cells; CD34 positive cells; Donor lymphocyte infusion; G CSF (filgrastim); Graft vs. leukemia effect; Lymphocyte apheresis

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; FLT3 LIGAND; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; AGED; APHERESIS; ARTICLE; BLOOD DONOR; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; IMMUNOMODULATION; LYMPHOCYTE; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RELAPSE; STEM CELL; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTIGENS, CD; BLOOD CELL COUNT; BLOOD DONORS; BODY WEIGHT; FEMALE; FILGRASTIM; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKAPHERESIS; LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034915851     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/jca.1017     Document Type: Article

References (30)

1. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
2. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation
3. Graft-versus-leukemia: No longer an epiphenomenon
4. Donor leukocyte infusions for relapse in chronic myelogenous leukemia
5. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukemia following BMT
6. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
7. Intensive chemotherapy followed by donor PBSC in ANNL relapsed after allogeneic BMT
8. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia
9. Graft-versus-myeloma effect: Proof of principle
10. Graft-versus-myeloma effect in two cases
11. Donor leukocyte infusion for post-bone marrow transplant relapse: Retrospective cohort analysis of 141 cases
12. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
13. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
14. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
15. Graft versus host disease as adoptive immunotherapy in patients with advanced hematologic malignancies
16. T cell depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect
17. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures
18. Graft-versus-leukemia reactions after bone marrow transplantation
19. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion
20. Bone marrow transplantation for chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of acute graft-versus-host disease but may increase the risk of leukaemic relapse
21. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukaemia
22. Adoptive immunotherapy: Insights from donor lymphocyte infusions
23. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation
24. dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease
25. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
26. Pretreatment of donor mice with granulocyte-colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
27. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia
28. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
29. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia